Cargando…

Correction: PARP targeted Auger emitter therapy with [(125)I]PARPi-01 for triple-negative breast cancer

Detalles Bibliográficos
Autores principales:	Sankaranarayanan, Ramya Ambur, Florea, Alexandru, Allekotte, Susanne, Vogg, Andreas T. J., Maurer, Jochen, Schäfer, Laura, Bolm, Carsten, Terhorst, Steven, Classen, Arno, Bauwens, Matthias, Morgenroth, Agnieszka, Mottaghy, Felix M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918701/ https://www.ncbi.nlm.nih.gov/pubmed/36763205 http://dx.doi.org/10.1186/s13550-023-00961-y

Ejemplares similares

PARP targeted Auger emitter therapy with [(125)I]PARPi-01 for triple-negative breast cancer
por: Ambur Sankaranarayanan, Ramya, et al.
Publicado: (2022)

Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study
por: Sankaranarayanan, Ramya Ambur, et al.
Publicado: (2022)

Correction: Sankaranarayanan et al. Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study. Cancers 2022, 14, 230
por: Sankaranarayanan, Ramya Ambur, et al.
Publicado: (2023)

Advancements in PARP1 Targeted Nuclear Imaging and Theranostic Probes
por: Ambur Sankaranarayanan, Ramya, et al.
Publicado: (2020)

Targeting of prostate-specific membrane antigen for radio-ligand therapy of triple-negative breast cancer
por: Morgenroth, Agnieszka, et al.
Publicado: (2019)

PARPi-FL - a Fluorescent PARP1 Inhibitor for Glioblastoma Imaging
por: Irwin, Christopher P., et al.
Publicado: (2014)

PARPi after PARPi in epithelial ovarian cancer
por: Essel, K.G., et al.
Publicado: (2021)

Observation of the Long Term Stability of Water Stations in the Pierre Auger Surface Detector
por: Allekotte, I
Publicado: (2005)

Two experts and a newbie: [(18)F]PARPi vs [(18)F]FTT vs [(18)F]FPyPARP—a comparison of PARP imaging agents
por: Stotz, Sophie, et al.
Publicado: (2021)

Modular Nanotransporters for Nuclear-Targeted Delivery of Auger Electron Emitters
por: Sobolev, Alexander S.
Publicado: (2018)

To PARPI or Not to PARPI BRCA Mutated Ovarian Cancer Following First-line Chemotherapy, That is the Question?
por: Rose, Peter G, et al.
Publicado: (2021)

Targeted Auger electron-emitter therapy: Radiochemical approaches for thallium-201 radiopharmaceuticals
por: Rigby, Alex, et al.
Publicado: (2021)

PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response
por: Riad, Aladdin, et al.
Publicado: (2020)

Hedgehog signaling sensitizes Glioma stem cells to endogenous nano-irradiation
por: Morgenroth, Agnieszka, et al.
Publicado: (2014)

BETting on combination to overcome PARPi resistance
por: Zhang, Youyou, et al.
Publicado: (2017)

In vitro proof of concept studies of radiotoxicity from Auger electron-emitter thallium-201
por: Osytek, Katarzyna M., et al.
Publicado: (2021)

Molecular Imaging of Angiogenesis in Oncology: Current Preclinical and Clinical Status
por: Florea, Alexandru, et al.
Publicado: (2021)

Preclinical Efficacy of a PARP-1 Targeted Auger-Emitting Radionuclide in Prostate Cancer
por: Sreekumar, Sreeja, et al.
Publicado: (2023)

Sodium [(18)F]Fluoride PET Can Efficiently Monitor In Vivo Atherosclerotic Plaque Calcification Progression and Treatment
por: Florea, Alexandru, et al.
Publicado: (2021)

Targeted Radionuclide Therapy Using Auger Electron Emitters: The Quest for the Right Vector and the Right Radionuclide
por: Idrissou, Malick Bio, et al.
Publicado: (2021)

Radioiodinated indomethacin amide for molecular imaging of cyclooxygenase-2 expressing tumors
por: Morgenroth, Agnieszka, et al.
Publicado: (2017)

Incorporation of iododeoxyuridine in multicellular glioma spheroids: implications for DNA-targeted radiotherapy using Auger electron emitters.
por: Neshasteh-Riz, A., et al.
Publicado: (1997)

Neural Stem Cells as Carriers of Nucleoside-Conjugated Nanogels: A New Approach toward Cell-Mediated Delivery
por: Morgenroth, Agnieszka, et al.
Publicado: (2023)

Ovarian cancer resistance to PARPi and platinum-containing chemotherapy
por: Summey, Rebekah, et al.
Publicado: (2022)

Platinum nanoparticles labelled with iodine-125 for combined “chemo-Auger electron” therapy of hepatocellular carcinoma
por: Wawrowicz, Kamil, et al.
Publicado: (2023)

Spectro Auger
Publicado: (1995)

Antitumor Activity of Auger Electron Emitter (111)In Delivered by Modular Nanotransporter for Treatment of Bladder Cancer With EGFR Overexpression
por: Rosenkranz, Andrey A., et al.
Publicado: (2018)

[(123)I]CC1: A PARP-Targeting, Auger Electron–Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer
por: Chan, Chung Ying, et al.
Publicado: (2023)

Preparation and Evaluation of Thermosensitive Liposomes Encapsulating I-125-Labeled Doxorubicin Derivatives for Auger Electron Therapy
por: Elghobary, Mohamed Elsaid Nasr, et al.
Publicado: (2023)

[(18)F]PARPi Imaging Is Not Affected by HPV Status In Vitro
por: Guru, Navjot, et al.
Publicado: (2021)

Fully Automated, High-Dose Radiosynthesis of [(18)F]PARPi
por: Pacelli, Anna, et al.
Publicado: (2022)

Construction of PARPi Resistance-related Competing Endogenous RNA Network
por: Kong, Lili, et al.
Publicado: (2022)

The Pierre Auger project
por: Mantsch, P M
Publicado: (1996)

The Pierre Auger Observatory
por: Swain, J D
Publicado: (2003)

Observatoire Pierre Auger
Publicado: (2009)

The theory of Auger transitions
por: Chattarji, D
Publicado: (1976)

Auger Prime Symposium
Publicado: (2015)

Modular nanotransporters: a versatile approach for enhancing nuclear delivery and cytotoxicity of Auger electron-emitting (125)I
por: Slastnikova, Tatiana A, et al.
Publicado: (2012)

Establishment and Molecular Characterization of an In Vitro Model for PARPi-Resistant Ovarian Cancer
por: Klotz, Daniel Martin, et al.
Publicado: (2023)

Horizontal auger boring projects
por: Atalah, Alan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_e4mmgugjg4dasdld8snmg5f5om